- Home
- MYN vs XOMA Comparison
MYN vs XOMA Comparison
Compare MYN & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYN
- XOMA
- Stock Information
- Founded
- MYN 1992
- XOMA 1981
- Country
- MYN United States
- XOMA United States
- Employees
- MYN N/A
- XOMA N/A
- Industry
- MYN Finance Companies
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- MYN Finance
- XOMA Health Care
- Exchange
- MYN Nasdaq
- XOMA Nasdaq
- Market Cap
- MYN 358.2M
- XOMA 330.2M
- IPO Year
- MYN N/A
- XOMA N/A
- Fundamental
- Price
- MYN $9.31
- XOMA $32.47
- Analyst Decision
- MYN
- XOMA Strong Buy
- Analyst Count
- MYN 0
- XOMA 2
- Target Price
- MYN N/A
- XOMA $69.50
- AVG Volume (30 Days)
- MYN 86.0K
- XOMA 57.0K
- Earning Date
- MYN 01-01-0001
- XOMA 08-13-2025
- Dividend Yield
- MYN 4.12%
- XOMA N/A
- EPS Growth
- MYN N/A
- XOMA N/A
- EPS
- MYN N/A
- XOMA N/A
- Revenue
- MYN N/A
- XOMA $44,952,000.00
- Revenue This Year
- MYN N/A
- XOMA $82.30
- Revenue Next Year
- MYN N/A
- XOMA $12.59
- P/E Ratio
- MYN N/A
- XOMA N/A
- Revenue Growth
- MYN N/A
- XOMA 194.98
- 52 Week Low
- MYN $8.47
- XOMA $18.35
- 52 Week High
- MYN $10.62
- XOMA $35.23
- Technical
- Relative Strength Index (RSI)
- MYN 48.18
- XOMA 61.79
- Support Level
- MYN $9.20
- XOMA $32.60
- Resistance Level
- MYN $9.33
- XOMA $34.60
- Average True Range (ATR)
- MYN 0.07
- XOMA 1.82
- MACD
- MYN -0.01
- XOMA 0.09
- Stochastic Oscillator
- MYN 50.00
- XOMA 66.75
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.